A detailed history of Clarius Group, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Clarius Group, LLC holds 16,686 shares of ABBV stock, worth $3.25 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
16,686
Previous 17,158 2.75%
Holding current value
$3.25 Million
Previous $3.12 Million 8.42%
% of portfolio
0.21%
Previous 0.22%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 11, 2024

SELL
$154.79 - $180.76 $73,060 - $85,318
-472 Reduced 2.75%
16,686 $2.86 Million
Q1 2024

Apr 17, 2024

SELL
$159.82 - $182.1 $282,721 - $322,134
-1,769 Reduced 9.35%
17,158 $3.12 Million
Q4 2023

Jan 29, 2024

BUY
$137.6 - $154.97 $465,225 - $523,953
3,381 Added 21.75%
18,927 $2.93 Million
Q3 2023

Oct 19, 2023

SELL
$133.59 - $154.65 $593,006 - $686,491
-4,439 Reduced 22.21%
15,546 $2.32 Million
Q2 2023

Aug 09, 2023

BUY
$132.51 - $164.9 $27,297 - $33,969
206 Added 1.04%
19,985 $2.69 Million
Q1 2023

Apr 17, 2023

BUY
$144.61 - $166.54 $87,922 - $101,256
608 Added 3.17%
19,779 $3.15 Million
Q4 2022

Jan 25, 2023

BUY
$138.31 - $165.87 $32,917 - $39,477
238 Added 1.26%
19,171 $3.1 Million
Q3 2022

Oct 24, 2022

BUY
$134.21 - $153.93 $62,139 - $71,269
463 Added 2.51%
18,933 $2.54 Million
Q2 2022

Aug 10, 2022

BUY
$137.62 - $174.96 $78,856 - $100,252
573 Added 3.2%
18,470 $2.83 Million
Q4 2021

Feb 02, 2022

BUY
$107.43 - $135.93 $42,434 - $53,692
395 Added 2.26%
17,897 $2.42 Million
Q3 2021

Oct 18, 2021

BUY
$106.4 - $120.78 $44,475 - $50,486
418 Added 2.45%
17,502 $1.89 Million
Q2 2021

Aug 06, 2021

BUY
$105.21 - $117.21 $21,252 - $23,676
202 Added 1.2%
17,084 $1.92 Million
Q1 2021

Apr 27, 2021

BUY
$102.3 - $112.62 $183,014 - $201,477
1,789 Added 11.85%
16,882 $1.83 Million
Q4 2020

Jan 15, 2021

BUY
$80.49 - $108.67 $108,017 - $145,835
1,342 Added 9.76%
15,093 $1.62 Million
Q3 2020

Oct 09, 2020

SELL
$85.91 - $100.83 $10,996 - $12,906
-128 Reduced 0.92%
13,751 $1.2 Million
Q2 2020

Jul 08, 2020

BUY
$73.37 - $98.18 $280,566 - $375,440
3,824 Added 38.03%
13,879 $1.36 Million
Q1 2020

Apr 24, 2020

BUY
$64.5 - $97.79 $19,092 - $28,945
296 Added 3.03%
10,055 $766,000
Q4 2019

Jan 22, 2020

BUY
$72.13 - $90.25 $57,776 - $72,290
801 Added 8.94%
9,759 $871,000
Q3 2019

Oct 23, 2019

SELL
$62.98 - $75.72 $48,935 - $58,834
-777 Reduced 7.98%
8,958 $678,000
Q2 2019

Aug 02, 2019

BUY
$65.7 - $83.98 $325,083 - $415,533
4,948 Added 103.36%
9,735 $708,000
Q1 2019

May 14, 2019

BUY
$77.14 - $90.79 $66,571 - $78,351
863 Added 21.99%
4,787 $386,000
Q4 2018

Feb 11, 2019

BUY
$77.85 - $96.01 $77,694 - $95,817
998 Added 34.11%
3,924 $362,000
Q3 2018

Nov 13, 2018

BUY
$88.91 - $98.84 $260,150 - $289,205
2,926 New
2,926 $277,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Clarius Group, LLC Portfolio

Follow Clarius Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clarius Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clarius Group, LLC with notifications on news.